Skip to content

PressReach

SEARCH icon
  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos
Search

SEARCH FOR AN ARTICLE

  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos

PressReach

icon

      HomeBiotech

      Biotech

      Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
      Biotech

      Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

      November 10, 2026
      Actinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical Development
      Biotech

      Actinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical Development

      November 10, 2026
      IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio
      Biotech

      IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio

      November 10, 2026
      MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026
      Biotech

      MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026

      November 9, 2026
      Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
      Biotech

      Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology

      November 9, 2026
      /C O R R E C T I O N – Edgewise Therapeutics/
      Biotech

      /C O R R E C T I O N – Edgewise Therapeutics/

      November 9, 2026
      VolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business Update
      Biotech

      VolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business Update

      November 9, 2026
      Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
      Biotech

      Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

      November 8, 2026
      IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
      Biotech

      IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses

      November 8, 2026
      argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
      Biotech

      argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities

      November 8, 2026
      « 1 … 7 8 9 10 11 … 176 »

       

      LATEST NEWS

      • Health Sanofi Market Potential Boosted by Amvuttra Data

      PressReach

      All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

      • Advertisers
      • Privacy Policy
      • Terms of Use
      • DMCA Policy
      • Disclaimer
      • Contact Us

      SUBSCRIBE

      To get email updates from PressReach.

      I want e-mail alerts, updates, and offers and agree to the PressReach privacy policy.

      Market Jar Media Inc. © 2026